The role of chemotherapy in the management of olfactory neuroblastoma: A 40‐year surveillance, epidemiology, and end results registry study
| Autor: | R.L. Deraniyagala, Thomas J. Quinn, Ryan J. Brisson |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Olfactory Neuroblastoma business.industry medicine.medical_treatment olfactory neuroblastoma Subgroup analysis General Medicine esthesioneuroblastoma medicine.disease chemotherapy Primary tumor Radiation therapy SEER Esthesioneuroblastoma Epidemiology Propensity score matching medicine Surveillance Epidemiology and End Results Medicine Radiology business chemoradiation Research Articles Research Article |
| Zdroj: | Health Science Reports Health Science Reports, Vol 4, Iss 2, Pp n/a-n/a (2021) |
| ISSN: | 2398-8835 |
| Popis: | Background In this retrospective surveillance, epidemiology, and end results (SEER) registry analysis, we investigated the role of chemotherapy (CT) in the treatment of olfactory neuroblastoma (ON), an exceedingly rare sino‐nasal tumor typically treated with surgery and/or radiation therapy (RT). Methods We analyzed all patients in the SEER registry diagnosed with a single primary malignancy of ON, a primary tumor site within the nasal cavity or surrounding sinuses, sufficient staging information to derive Kadish staging, and >0 days of survival, ensuring follow‐up data. Receipt of CT in the SEER registry was documented as either Yes or No/Unknown. Results Six hundred and thirty‐six patients were identified. One hundred and ninety‐five patients received CT as part of their treatment for ON. Following propensity score matching and inverse probability of treatment weighting, there was inferior overall survival (OS) (HR 1.7, 95% CI: 1.3‐2.2, P = .001) and cancer‐specific survival (CSS) (HR 1.8, 95% CI: 1.3‐2.4, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text